867 related articles for article (PubMed ID: 28231819)
1. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
3. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
4. [Neoantigens and Whole-Exome Sequencing].
Karasaki T; Nakajima J; Kakimi K
Gan To Kagaku Ryoho; 2016 Jul; 43(7):791-7. PubMed ID: 27431622
[TBL] [Abstract][Full Text] [Related]
5. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
7. Computational Prediction and Validation of Tumor-Associated Neoantigens.
Roudko V; Greenbaum B; Bhardwaj N
Front Immunol; 2020; 11():27. PubMed ID: 32117226
[TBL] [Abstract][Full Text] [Related]
8. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
9. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
10. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
13. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
[TBL] [Abstract][Full Text] [Related]
14. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
15. Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
Front Immunol; 2019; 10():1856. PubMed ID: 31440245
[TBL] [Abstract][Full Text] [Related]
16. Personalized cancer vaccines: Targeting the cancer mutanome.
Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
[TBL] [Abstract][Full Text] [Related]
17. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
18. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M; Farrel A; Sison A; di Marco M; Raman P; Parris JL; Monos D; Lee H; Stevanovic S; Maris JM
Front Immunol; 2020; 11():69. PubMed ID: 32256484
[TBL] [Abstract][Full Text] [Related]
20. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
